Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT01302691 Completed - Hypertension Clinical Trials

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

Start date: January 1, 2011
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5 in Japanese participants with essential hypertension who are not adequately controlled following an 8-week treatment with filter period study drug (L50+A5).

NCT ID: NCT01295021 Completed - Clinical trials for Essential Hypertension

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.

SORT
Start date: February 2011
Phase: N/A
Study type: Observational

The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.

NCT ID: NCT01289899 Completed - Clinical trials for Essential Hypertension

Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects

Start date: January 2004
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.

NCT ID: NCT01289886 Completed - Clinical trials for Essential Hypertension

Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects

Start date: September 2003
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.

NCT ID: NCT01289132 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.

NCT ID: NCT01264692 Completed - Clinical trials for Essential Hypertension

Essential Hypertension

REDUCE-1
Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

NCT ID: NCT01258673 Completed - Clinical trials for Essential Hypertension

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Start date: November 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.

NCT ID: NCT01256411 Completed - Clinical trials for Essential Hypertension

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.

NCT ID: NCT01237873 Completed - Clinical trials for Essential Hypertension

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension. This study is being conducted to support registration of the fixed combination of aliskiren/amlodipine in the treatment for hypertension in Japan.

NCT ID: NCT01237223 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Start date: October 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥ 95 mmHg and < 110 mmHg and mean sitting systolic blood pressure [msSBP] ≥ 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan.